Department of Anesthesiology, Ankara Atatürk Sanatoryum Training and Research Hospital, Kecioren, Ankara, Turkey.
Eur Rev Med Pharmacol Sci. 2023 Oct;27(19):9429-9437. doi: 10.26355/eurrev_202310_33971.
COVID-19 disease bears similarities to a wide range of diseases, from simple flu infections to severe acute respiratory distress syndrome and is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In this study, we aimed to elucidate the plateletcrit levels in patients with and without mortality who had been admitted to the intensive care unit because of pneumonia associated with SARS-CoV-2.
In total, 434 patients were evaluated in this retrospective analysis. Their demographic data, comorbid diseases, Acute Physiology and Chronic Health Evaluation (APACHE) II and Sequential Organ Failure Assessment (SOFA) scores, platelet, lymphocyte, white blood cell (WBC) and neutrophil counts; mean platelet volume (MPV), platelet distribution width (PDW), plateletcrit (PCT), hemoglobin and C-reactive protein (CRP) levels and neutrophil-lymphocyte ratios (NLRs) were obtained from the hospital's electronic database on the days of the patients' intensive care unit admissions. Afterwards, their PLR, PNR, and MPV/PLT ratios were calculated.
APACHE II score, length of hospital stay, WBC count, PCT, PLR, NLR, and CRP levels affected mortality. Increases in hospital stay duration, APACHE II score, platelet-lymphocyte ratio (PLR), and CRP, as well as decreases in PCT percentage, were associated with mortality. ROC curve analysis was performed to determine the success of PCT, PLR, and NLR in predicting mortality in COVID-19 patients and to determine cut-off values for mortality. It was determined that PCT, PLR, and NLR could correctly classify patients at rates of 58.9%, 59.2%, and 66.8% (moderate), respectively. The risk of mortality was higher in patients with PCT values of 0.188 or less, PLR values greater than 293.46, and NLR values greater than 9.49.
In the COVID-19 patients evaluated in this study, plateletcrit indices could be utilized to predict mortality.
COVID-19 疾病与多种疾病具有相似性，从简单的流感感染到严重的急性呼吸窘迫综合征，其由严重急性呼吸综合征冠状病毒-2（SARS-CoV-2）引起。在本研究中，我们旨在阐明因 SARS-CoV-2 相关肺炎而入住重症监护病房的有和无死亡患者的血小板crit 水平。
在这项回顾性分析中，共评估了 434 名患者。从医院的电子数据库中获取了他们的人口统计学数据、合并症、急性生理学和慢性健康评估（APACHE）Ⅱ和序贯器官衰竭评估（SOFA）评分、血小板、淋巴细胞、白细胞（WBC）和中性粒细胞计数；平均血小板体积（MPV）、血小板分布宽度（PDW）、血小板crit（PCT）、血红蛋白和 C-反应蛋白（CRP）水平以及中性粒细胞-淋巴细胞比值（NLR），并在患者入住重症监护病房的当天进行了记录。之后，计算了他们的 PLR、PNR 和 MPV/PLT 比值。
APACHE Ⅱ评分、住院时间、WBC 计数、PCT、PLR、NLR 和 CRP 水平影响死亡率。住院时间延长、APACHE Ⅱ评分升高、血小板-淋巴细胞比值（PLR）和 CRP 升高以及 PCT 百分比降低与死亡率相关。进行了 ROC 曲线分析，以确定 PCT、PLR 和 NLR 在预测 COVID-19 患者死亡率方面的成功，并确定死亡率的截断值。结果表明，PCT、PLR 和 NLR 可分别以 58.9%、59.2%和 66.8%（中等）的比例正确分类患者。PCT 值小于或等于 0.188、PLR 值大于 293.46 和 NLR 值大于 9.49 的患者的死亡率更高。
在本研究中评估的 COVID-19 患者中，血小板crit 指数可用于预测死亡率。
